Loading...

APC anti-human CD279 (PD-1) Antibody APC anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-EH12dot2H7_APC_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • a-EH12dot2H7_APC_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • b-EH12-2H7_APC_CD279_2_Antibody_103024
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC and CD3 (clone UCHT1) PerCP/Cyanine5.5.
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
329907 25 tests DKK886
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329908 100 tests DKK1866
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed
  2. Gao Y, et al. 2023. JCI Insight. 8: . PubMed
  3. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  4. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  5. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  6. Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed
  7. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  8. Imai H, et al. 2023. iScience. 26:106822. PubMed
  9. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  10. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  11. Wang Z, et al. 2018. Nat Commun. 9:824. PubMed
  12. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  13. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  14. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  15. Panwar B, et al. 2021. Genome Res. 31:659. PubMed
  16. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  17. Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed
  18. Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed
  19. Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed
  20. Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed
  21. Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed
  22. Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed
  23. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  24. Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed
  25. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  26. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  27. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  28. Zhang J, et al. 2022. Nature. 609:369. PubMed
  29. Cai J, et al. 2021. eLife. 10:00. PubMed
  30. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  31. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  32. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  33. Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed
  34. Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed
  35. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  36. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  37. Wang D, et al. 2017. Leukemia. 10.1038/leu.2017.69. PubMed
  38. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  39. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  40. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  41. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  42. Niu C, et al. 2018. Front Immunol. 9:1759. PubMed
  43. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  44. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  45. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  46. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  47. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  48. Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed
  49. Tian X, et al. 2015. J Immunol. 194:3873. PubMed
  50. Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed
  51. Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
  52. Lecciso M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01918. PubMed
  53. Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
  54. Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed
  55. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
  56. Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed
  57. Gao Y, et al. 2023. JCI Insight. 8: . PubMed
  58. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  59. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  60. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  61. Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed
  62. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  63. Imai H, et al. 2023. iScience. 26:106822. PubMed
  64. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  65. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  66. Wang Z, et al. 2018. Nat Commun. 9:824. PubMed
  67. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  68. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  69. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  70. Panwar B, et al. 2021. Genome Res. 31:659. PubMed
  71. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  72. Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed
  73. Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed
  74. Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed
  75. Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed
  76. Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed
  77. Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed
  78. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  79. Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed
  80. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  81. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  82. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  83. Zhang J, et al. 2022. Nature. 609:369. PubMed
  84. Cai J, et al. 2021. eLife. 10:00. PubMed
  85. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  86. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  87. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  88. Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed
  89. Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed
  90. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  91. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  92. Wang D, et al. 2017. Leukemia. 10.1038/leu.2017.69. PubMed
  93. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  94. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  95. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  96. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  97. Niu C, et al. 2018. Front Immunol. 9:1759. PubMed
  98. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  99. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  100. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  101. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  102. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  103. Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed
  104. Tian X, et al. 2015. J Immunol. 194:3873. PubMed
  105. Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed
  106. Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
  107. Lecciso M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01918. PubMed
  108. Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
  109. Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed
  110. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
RRID
AB_940473 (BioLegend Cat. No. 329907)
AB_940475 (BioLegend Cat. No. 329908)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC,CyTOF®
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC,SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
Spark Red™ 718 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 744 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 570™ anti-human CD279 (PD-1) EH12.2H7 FC
Spark NIR™ 685 anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Spark PLUS B550™ anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Spark YG™ 581 anti-human CD279 (PD-1) (Flexi-Fluor™) EH12.2H7 FC
Spark YG™ 593 anti-human CD279 (PD-1) (Flexi-Fluor™) Antibody EH12.2H7 FC
StarBright UltraViolet 740 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 700 anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Go To Top Version: 2    Revision Date: 01/22/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-EH12dot2H7_APC_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • a-EH12dot2H7_APC_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • b-EH12-2H7_APC_CD279_2_Antibody_103024
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC and CD3 (clone UCHT1) PerCP/Cyanine5.5.
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
329907 25 tests DKK886
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329908 100 tests DKK1866
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed
  2. Gao Y, et al. 2023. JCI Insight. 8: . PubMed
  3. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  4. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  5. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  6. Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed
  7. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  8. Imai H, et al. 2023. iScience. 26:106822. PubMed
  9. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  10. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  11. Wang Z, et al. 2018. Nat Commun. 9:824. PubMed
  12. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  13. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  14. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  15. Panwar B, et al. 2021. Genome Res. 31:659. PubMed
  16. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  17. Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed
  18. Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed
  19. Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed
  20. Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed
  21. Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed
  22. Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed
  23. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  24. Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed
  25. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  26. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  27. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  28. Zhang J, et al. 2022. Nature. 609:369. PubMed
  29. Cai J, et al. 2021. eLife. 10:00. PubMed
  30. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  31. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  32. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  33. Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed
  34. Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed
  35. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  36. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  37. Wang D, et al. 2017. Leukemia. 10.1038/leu.2017.69. PubMed
  38. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  39. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  40. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  41. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  42. Niu C, et al. 2018. Front Immunol. 9:1759. PubMed
  43. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  44. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  45. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  46. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  47. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  48. Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed
  49. Tian X, et al. 2015. J Immunol. 194:3873. PubMed
  50. Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed
  51. Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
  52. Lecciso M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01918. PubMed
  53. Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
  54. Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed
  55. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
  56. Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed
  57. Gao Y, et al. 2023. JCI Insight. 8: . PubMed
  58. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  59. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  60. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  61. Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed
  62. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  63. Imai H, et al. 2023. iScience. 26:106822. PubMed
  64. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  65. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  66. Wang Z, et al. 2018. Nat Commun. 9:824. PubMed
  67. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  68. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  69. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  70. Panwar B, et al. 2021. Genome Res. 31:659. PubMed
  71. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  72. Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed
  73. Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed
  74. Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed
  75. Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed
  76. Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed
  77. Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed
  78. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  79. Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed
  80. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  81. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  82. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  83. Zhang J, et al. 2022. Nature. 609:369. PubMed
  84. Cai J, et al. 2021. eLife. 10:00. PubMed
  85. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  86. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  87. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  88. Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed
  89. Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed
  90. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  91. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  92. Wang D, et al. 2017. Leukemia. 10.1038/leu.2017.69. PubMed
  93. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  94. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  95. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  96. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  97. Niu C, et al. 2018. Front Immunol. 9:1759. PubMed
  98. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  99. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  100. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  101. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  102. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  103. Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed
  104. Tian X, et al. 2015. J Immunol. 194:3873. PubMed
  105. Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed
  106. Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
  107. Lecciso M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01918. PubMed
  108. Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
  109. Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed
  110. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
RRID
AB_940473 (BioLegend Cat. No. 329907)
AB_940475 (BioLegend Cat. No. 329908)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC,CyTOF®
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC,SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
Spark Red™ 718 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 744 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 570™ anti-human CD279 (PD-1) EH12.2H7 FC
Spark NIR™ 685 anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Spark PLUS B550™ anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Spark YG™ 581 anti-human CD279 (PD-1) (Flexi-Fluor™) EH12.2H7 FC
Spark YG™ 593 anti-human CD279 (PD-1) (Flexi-Fluor™) Antibody EH12.2H7 FC
StarBright UltraViolet 740 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 700 anti-human CD279 (PD-1) Antibody EH12.2H7 FC
Go To Top Version: 2    Revision Date: 01/22/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account